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Background: Activation signals can be negatively regulated by cell surface receptors bearing immunoreceptor
tyrosine-based inhibitory motifs (ITIMs). CD300a, an ITIM bearing type I transmembrane protein, is expressed on
many hematopoietic cells, including subsets of lymphocytes.
Results: We have taken two approaches to further define the mechanism by which CD300a acts as an inhibitor of
immune cell receptor signaling. First, we have expressed in Jurkat T cells a chimeric receptor consisting of the
extracellular domains of killer-cell immunoglobulin-like receptor (KIR)2DL2 fused to the transmembrane and
cytoplasmic segments of CD300a (KIR-CD300a) to explore surrogate ligand-stimulated inhibition of superantigen
stimulated T cell receptor (TCR) mediated cell signaling. We found that intact CD300a ITIMs were essential for
inhibition and that the tyrosine phosphorylation of these ITIMs required the src tyrosine kinase Lck. Tyrosine
phosphorylation of the CD300a ITIMs created docking sites for both src homology 2 domain containing protein
tyrosine phosphatase (SHP)-1 and SHP-2. Suppression of SHP-1 and SHP-2 expression in KIR-CD300a Jurkat T cells
with siRNA and the use of DT40 chicken B cell lines expressing CD300a and deficient in several phosphatases
revealed that SHP-1, but not SHP-2 or the src homology 2 domain containing inositol 5’ phosphatase SHIP, was
utilized by CD300a for its inhibitory activity.
Conclusion: These studies provide new insights into the function of CD300a in tuning T and B cell responses.Background
An appropriate immune response requires a fine balance
between a multitude of activating and inhibitory signals
and the loss of the ability to limit positive signaling can
result in autoreactivity and excessive inflammation [1,2].
A diverse array of inhibitory receptors participates in the
negative control of the immune response. A characteris-
tic of many of these receptors is a consensus amino acid
sequence in their cytoplasmic tail, i.e. the immunorecep-
tor tyrosine-based inhibitory motif (ITIM) [3-8]. Ligand
interaction with these receptors results in ITIM tyrosine
phosphorylation, usually by a src family kinase, providing
sites for binding proteins via their src-homology 2 (SH2)
domains [9-14]. Proteins containing consensus sequences
for interaction with phosphorylated ITIMs include the* Correspondence: Francisco.Borrego@fda.hhs.gov
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reproduction in any medium, provided the orSH2 domain-containing tyrosine phosphatase (SHP)-1,
SHP-2, and the SH2 domain-containing inositol
5’-phosphatase (SHIP) [10,13-16]. The recruitment of
phosphatases to the phosphorylated ITIMs results in
their activation and the subsequent dephosphorylation of
their substrates, leading to the down-regulation of activa-
tion signals [9-14]. Although several targets of these
phosphatases have been proposed, the specific pathways
and mechanisms by which each phosphatase participates
in the signaling cascade downstream from the inhibitory
receptors remain incompletely understood [17-19].
CD300a is one of the seven members of the CD300
family of leukocyte surface receptors that are encoded by
genes clustered in human chromosome 17q25 [20]. Like
the other members of the CD300 family, CD300a is a
type I transmembrane protein, with a single IgV-like
extracellular region and three classical and one non-
classical ITIMs in its cytoplasmic tail [20]. The CD300a
gene has undergone a very significant positive selection,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tain its function throughout evolution [21,22]. CD300a is
expressed on cells of both the myeloid and lymphoid
lineages [20]. The clinical relevance of this receptor is
demonstrated in reports showing the association of a
non-synonymous polymorphism within the Ig-V domain
with the development of psoriasis [23], the implication
in the development of Alzheimer’s disease by genome
wide association studies [24], the down-regulation of
CD300a expression on B cells from HIV-1 infected
patients [25], and the proposed use of CD300a as a bio-
marker that can differentiate ulcerative colitis from
Crohn’s disease and non-inflammatory diarrhea [26] and
for the detection of minimal residual disease in acute
lymphoblastic leukemia [27].
In vitro studies have shown that CD300a ligation can
inhibit NK cell mediated cytotoxicity [28,29], FcεRI
mediated activation of mast cells [30], FcγRIIa mediated
reactive oxygen species production and Ca2+ flux in neu-
trophils [31] and eosinophils responses to eotaxin, GM-
CSF and IL-5 [32]. Additionally, it has been shown to in-
hibit both B cell receptor (BCR) and T cell receptor
(TCR) mediated Ca2+ mobilization and NFAT mediated
transcriptional activity [25,33]. Furthermore, in vivo
studies in mice have shown that CD300a is able to re-
verse remodeling and airway inflammation in a model of
experimental asthma [34], to abrogate IgE mediated al-
lergic reactions [35] and to inhibit stem cell factor (SCF)
induced anaphylaxis [36]. Various mechanisms of the
CD300a mediated inhibitory signaling have been pro-
posed. Several publications have shown that phosphory-
lated CD300a is able to recruit different phosphatases
depending on the examined cell type, although genetic
evidences for the direct involvement of any phosphatase
in the delivery of CD300a mediated inhibitory signal is
lacking. For example, treatment of human NK cells with
pervanadate led to tyrosine phosphorylation of CD300a
and its association with both SHP-1 and SHP-2 [28],
while in eosinophils cross-linking of the receptor with
monoclonal antibodies (mAb) recruited SHP-1 but not
SHP-2 [32]. In mast cells, after pervanadate treatment,
SHP-1 and SHIP, but not SHP-2 co-precipitated with
CD300a, while upon mAb driven cross-linking, SHIP,
but not SHP-1 associated with CD300a [30]. Also in
mast cells, precipitation of CD300a from cells treated
with an anti-Kit-CD300a bispecific antibody induced its
tyrosine phosphorylation and the recruitment of SHIP,
but not SHP-1 [36].
In T and B lymphocytes the expression of CD300a is
restricted to certain subsets [25,33,37,38]. Although it
has been previously shown that ligation of CD300a with
mAb inhibits BCR [25] and TCR mediated signals [33],
the basis for this inhibition is not known. In this study
we investigate the structural and functional requirementsfor CD300a mediated inhibitory signaling in B and T
cells. Importantly, we establish a physiologically relevant
model in which we explore ligand driven functions of
CD300a. To accomplish this, a KIR-CD300a chimera was
expressed in Jurkat T cells. Mixing these cells with MHC
class I matched antigen presenting cells that were loaded
with superantigen allowed us to determine the import-
ance of the CD300a ITIMs, the means by which they are
phosphorylated and the phosphatases that subsequently
associate with them. Further studies, using DT40 B cell
lines and siRNA mediated knock down of SHP-1 and
SHP-2 in Jurkat T cells, were performed to discriminate
among signaling intermediates utilized by CD300a.
Results
Intact ITIM motifs are required for CD300a mediated
inhibitory signal
Recently, we have demonstrated that the immunomodu-
latory receptor CD300a is expressed in certain subsets of
human B and T cells and that it functions as a negative
regulator of B and T cell signaling [25,33,38]. To explore
the structural requirements for the CD300a mediated in-
hibitory signal, we have engineered plasmids encoding
the CD300a receptor that have the tyrosine residues in
the four ITIMs mutated to phenylalanine. The DT40
chicken B cell line was stably transfected with plasmids
encoding the wild type CD300a receptor (CD300a WT)
or the CD300a tyrosine to phenylalanine mutant recep-
tor (CD300a 4F). We then examined the inhibitory
effects of CD300a ligation on two BCR mediated events.
As we have previously shown [25], coligation of the BCR
with CD300a WT using mAb, resulted in a decreased
rise of intracellular Ca2+ and a diminished NFAT tran-
scriptional activity when compared with ligation of the
BCR alone. However, when the experiments were per-
formed with DT40 chicken B cells expressing CD300a
4F, no decrease in these BCR mediated events was
observed (Figure 1). These results indicate that CD300a
mediated inhibition of BCR driven signals is dependent
on intact ITIMs.
The intracellular tail of CD300a inhibits superantigen
mediated activation of T cells
The above results and those published by others have
shown that ligation of CD300a with mAb delivers an in-
hibitory signal in a variety of cell types [25,28-32,36]. We
sought to investigate the inhibitory signaling potential of
CD300a in a system that, instead, relies on receptor-
ligand interaction. To do that we established stably
transfected Jurkat T cell lines expressing a chimeric re-
ceptor that retains the transmembrane segment and the
intracellular tail of CD300a but substitutes the extracel-
lular portion of the receptor with that of KIR2DL2 whose
ligands are the MHC Class I molecules HLA-Cw1, -Cw3,
Figure 1 The ITIMs of CD300a are essential for the inhibition of BCR stimulated activation. (A) DT40 chicken B cells expressing CD300a WT
or CD300a 4F were loaded with Fluo-4 and Fura-Red. Cells were stimulated with anti-chicken BCR plus isotype control antibody (black line) or
anti-chicken BCR plus anti-CD300a mAb (grey line) for 30 seconds and then co-crosslinked with a secondary antibody (GAM). Fluorescence
emission was measured in a flow cytometer. Ca2+ mobilization is expressed as the ratio of Fluo-4/Fura-Red as a function of time. These results are
representative of three independent experiments. (B) DT40 chicken B cells expressing CD300a WT or CD300a 4F were transiently transfected with
a NFAT luciferase reporter plasmid and stimulated with GAM plus anti-chicken BCR plus isotype control or anti-chicken BCR plus anti-CD300a
mAb. The measured luciferase activity was normalized to the activity obtained with cells treated with PMA plus ionomycin. Data are presented as
percentage of inhibition of CD300a vs. isotype control and they are the average ± SEM for three separate experiments.
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at the C terminal end. Two Jurkat T cell lines were estab-
lished: KIR-CD300a WT, which conserves the wild type
sequence of the intracellular tail of CD300a, and KIR-
CD300a 4F, that has the tyrosine residues of the four
CD300a ITIMs mutated to phenylalanine (Figure 2).
To study the ability of KIR-CD300a to inhibit TCR
mediated signaling, we utilized a system that relies on
the activation of Jurkat T cells by the bacterial superanti-
gen SED, which binds the TCR Vβ chain. In our experi-
mental design, SED is presented by MHC class II
molecules expressed on the human B cell line 721.221.
When Jurkat T cells were stimulated with the HLA-C
negative 721.221 cells loaded with SED, an increase in
the expression of the activation marker CD69 was
observed. This occurred whether or not the Jurkat T cells
expressed the KIR-CD300a WT or the KIR-CD300a 4F
chimeric receptors. However, when SED was presented
by 721.221 cells expressing the KIR2DL2 ligand HLA-
Cw3 (721.221-Cw3), we observed a significant reduction
in the upregulation of CD69 expression by KIR-CD300a
WT Jurkat T cells. Conversely, presentation of SED by
721.221-Cw3 cells did not affect the upregulation of
CD69 expression on KIR-CD300a 4F Jurkat T cells
(Figure 3A and B). Similar results were obtained whenwe measured the expression of another activation mar-
ker, i.e. CD25 (Figure 3C). These results indicate that the
intracellular tail of CD300a is responsible for inhibiting
superantigen mediated activation signals, and confirm
that the inhibitory signal requires intact ITIMs.
To further prove that the intracellular tail of CD300a
is responsible for the inhibitory signal we performed
additional experiments measuring NFAT transcrip-
tional activity. We transiently transfected the E6.1 Jur-
kat T cell line and the KIR-CD300a WT and KIR-
CD300a 4F expressing Jurkat T cells with a plasmid
encoding the luciferase reporter gene under the con-
trol of a NFAT dependent promoter. Cells were stimu-
lated through the TCR with SED presented by 721.221,
721.221-Cw3 and 721.221-Cw6 cells. The MHC class I
molecule HLA-Cw6 is not a ligand for KIR2DL2 [39].
Results in Figure 3D showed that there was a decrease
in the NFAT transcriptional activity only when KIR-
CD300a WT Jurkat T cells were stimulated with SED
solely presented by 721.221-Cw3 cells, and not
721.221 or 721.221-Cw6 cells. These results confirmed
that the inhibition of superantigen mediated activation
of Jurkat T cells required both the specific interaction
between KIR2DL2 with its ligand, HLA-Cw3, and an
intact CD300a intracellular tail.
Figure 2 Schematic representation of the chimeric KIR-CD300a
receptors. Structure of the chimeric molecules bearing the
extracellular domain of KIR2DL2 and the transmembrane and
cytoplasmic domains of CD300a is represented. The construct is
fused to the hemagglutinin (HA) tag at the C-terminus. The shady
dotted regions in the cytoplasmic tail correspond to the ITIMs in the
CD300a receptor. The tyrosine in each of the 4 ITIMs was mutated to
phenylalanine to generate the mutant chimeric construct KIR-
CD300a 4F.
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phosphorylation of CD300a on Jurkat T cells
Interaction of ITIM containing receptors with their ligands
leads to ITIM tyrosine phosphorylation. To demonstrate
that CD300a ITIMs are tyrosine phosphorylated in
response to KIR2DL2 ligand in our experimental system,
KIR-CD300a WT and KIR-CD300a 4F Jurkat T cells were
mixed with 721.221-Cw3 and 721.221-Cw6 cells and
then anti-KIR2DL2 immunoprecipitates from celllysates were examined by western blot analysis
(Figure 4). We observed that KIR-CD300a WT was
tyrosine phosphorylated when Jurkat T cells interacted
with 721.221-Cw3 cells but not with 721.221-Cw6
cells. Pervanadate treatment was used as a positive
control. As expected, co-culture of KIR-CD300a 4F
Jurkat T cells with 721.221-Cw3 cells did not cause
KIR-CD300a 4F phosphorylation (Figure 4A).
It has been previously described that the src kinase
Lck is required for KIR tyrosine phosphorylation [9]. In
our experimental system, in order to identify the kinase
responsible for phosphorylation of CD300a ITIMs, the
E6.1 Jurkat T cell line and the Jurkat T cell lines deficient
in Lck or ZAP-70 were transiently transfected with a
plasmid encoding KIR-CD300a WT. These cells were
mixed with 721.221-Cw3 or 721.221-Cw6 cells and tyro-
sine phosphorylation was assessed in KIR2DL2 immuno-
precipitates (Figure 4B). Co-incubation of 721.221-Cw3
cells with either the E6.1 Jurkat T cell line or the ZAP-70
deficient cells led to tyrosine phosphorylation of KIR-
C300a, indicating that ZAP-70 is not necessary for tyro-
sine phosphorylation of the intracellular tail of CD300a.
However, when Jurkat T cells deficient in Lck were incu-
bated with 721.221-Cw3, tyrosine phosphorylation of
KIR-CD300a was not observed in any of the immunopre-
cipitates. As expected, co-incubation of any Jurkat T cell
lines with 721.221-Cw6 cells did not stimulate tyrosine
phosphorylation of KIR-CD300a WT. Together, these
results show that ligand-receptor interaction leads to
tyrosine phosphorylation of the CD300a ITIMs in the
absence of an activation signal, and that the src kinase
Lck is responsible for tyrosine phosphorylation of the
CD300a ITIM motifs in Jurkat T cells.
Both SHP-1 and SHP-2 bind to CD300a ITIM, but only
SHP-1 is necessary for CD300a mediated inhibition
Tyrosine phosphorylation of ITIMs creates docking sites
for SH2 domain containing proteins. ITIMs are known
to specifically recruit phosphatases including SHP-1,
SHP-2 and SHIP [13-16,40]. To identify potential phos-
phatases that bind to CD300a ITIMs, KIR-CD300a WT
Jurkat T cells were treated with pervanadate or mixed
with 721.221-Cw3 and 721.221-Cw6 cells and anti-KIR
immunoprecipitates were probed with antibodies to
SHP-1 and SHP-2. Both SHP-1 and SHP-2 coprecipi-
tated with KIR-CD300a WT when cells were either trea-
ted with pervanadate or cocultured with 721.221-Cw3
cells but not 721.221-Cw6 cells (Figure 5). As expected,
neither phosphatase coprecipitated with KIR-CD300a 4F
(data not shown). Binding of SHIP to CD300a ITIMs
could not be assessed in this system since Jurkat T cells
do not express this phosphatase (data not shown).
In order to ascertain which of the phosphatases were re-
sponsible for the CD300a mediated inhibitory response,
Figure 3 KIR-CD300a mediates inhibition of SED stimulated Jurkat T cell activation. (A) Gating strategy for assessing CD69 expression on
superantigen activated cells. Jurkat T cells were electronically gated by size and forward scatter and by the absence of expression of CD19, a marker of
721.221 cells, and then the expression of CD69 was assessed. The gating strategy for assessing CD25 expression was the same. (B) KIR CD300a WT and
KIR-CD300a 4F Jurkat T cells were co-cultured with 721.221 or 721.221-Cw3 cells, loaded or not with SED. Cultures were harvested and Jurkat T cells
were assessed for CD69 expression by flow cytometry. Results are representative of three independent experiments. (C) Cells were cultured as in B,
loaded (white bar) or not (black bars) with SED, and the expression of CD25 was assessed. The bar graph represents average ± SEM of the percentage
of CD25+ Jurkat T cells. Results are from three independent experiments. (D) Untransfected E6.1, KIR-CD300a WT and KIR-CD300a 4F Jurkat T cells were
transiently transfected with a NFAT luciferase reporter plasmid. Following coculture with 721.221, 721.221-Cw3 and 721.221-Cw6 loaded (withe bars) or
not (black bars) with SED, cells were lysed and supernatants were assayed for luciferase activity. Data were normalized by the activity obtained with
cells treated with PMA plus ionomycin. Results are representative of three independent experiments.
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Figure 4 Tyrosine phosphorylation of CD300a requires the src
kinase Lck. (A) KIR-CD300a WT and KIR-CD300a 4F Jurkat T cells
were stimulated with medium or pervanadate for 3 minutes, or
mixed with 721.221-Cw3 or 721.221-Cw6 and incubated at 37°C for
5 minutes. Cell lysates were immunopreciprecipitated with anti-
KIR2DL2 (clone GL183) mAb and blotted separately for
phosphotyrosine and HA. Results are representative of five
independent experiments. (B) E6.1 Jurkat cells, Jurkat cells deficient
in Lck or deficient in ZAP-70 were transiently transfected with a
plasmid encoding KIR-CD300a and incubated at 37°C with 721.221-
Cw3 and 721.221-Cw6 for 5 minutes. Cell lysates were
immunoprecipitated with anti-KIR2DL2 (clone GL183) mAb and
blotted separately for phosphotyrosine and HA. Results are
representative of three independent experiments.
Figure 5 The phosphatases SHP-1 and SHP-2 associate with
tyrosine phosphorylated CD300a ITIMs. KIR-CD300a Jurkat T cells
were stimulated with medium or pervanadate for 3 minutes, or
incubated for 5 minutes at 37°C with 721.221-Cw3 and 721.221-Cw6
cells. Then, cell lysates were immunopreciprecipitated with anti-
KIR2DL2 (clone GL183) mAb and blotted separately for HA, SHP-1
and SHP-2. Results are representative of two independent
experiments.
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availability of cell lines lacking SHP-1, SHP-2 or SHIP.
Stable transfectants expressing CD300a WT were estab-
lished in each of these cell lines and they were tested for
inhibition of BCR stimulated Ca2+ mobilization. In SHP-2
and SHIP lacking DT40 chicken B cells, the coligation of
the BCR with CD300a WT resulted in a decrease in the
BCR stimulated rise of intracellular Ca2+ concentration
similar to that obtained with wild type DT40 chicken B
cells, suggesting that SHP-2 and SHIP do not have a pri-
mary role in the transmission of the CD300a inhibitory
signal. On the other hand, the CD300a mediated inhibition
of BCR induced Ca2+ mobilization was largely abolished in
cells lacking SHP-1 (Figure 6A). The dominant role of
SHP-1 in CD300a inhibitory signal was confirmed by a sig-
nificant decrease in the CD300a mediated inhibition of
BCR induced NFAT transcriptional activity in the SHP-1
deficient cells (Figure 6B). To further demonstrate the spe-
cific employment of SHP-1, we reconstituted SHP-1 defi-
cient DT40 chicken B cells with human SHP-1 WT and
SHP-1 CS. While the expression of human SHP-1 WT
restored the inhibitory activity of CD300a, expression of
SHP-1 CS, an inactive version of the phosphatase, did not
(Figure 6C). We also reconstituted the SHP-2 deficientDT40 chicken B cells with human SHP-2 WT and SHP-2
CS. The expression of both human SHP-2 WT and SHP-2
CS resulted in a decrease in the CD300a mediated inhib-
ition of BCR induced Ca2+ release when compared to
SHP-2 deficient cells (Figure 6C). Finally, we efficiently
suppressed the expression of SHP-1 and SHP-2 in the
KIR-CD300a WT Jurkat T cells with specific siRNA.
Results showed that while knock down of SHP-2 in KIR-
CD300a WT Jurkat T cells has no effect in inhibiting
CD69 induced expression after stimulation with 721.221-
Cw3 cells loaded with SED, the SHP-1 knock down
resulted in a decrease in the inhibitory potential of KIR-
CD300a WT in suppressing CD69 induced expression
after stimulation with SED loaded 721.221-Cw3 cells
(Figure 6D). Taken together, these results indicate that al-
though both SHP-1 and SHP-2 bind CD300a ITIMs, SHP-
1 is the dominant phosphatase in the CD300a mediated
signaling pathway, while SHP-2 and SHIP do not have a
significant role.
Discussion
In this report, we provide evidence that the primary
function of CD300a in T and B cells is to limit antigen
receptor mediated positive signaling and that the phos-
phatase SHP-1 is required for this function. Coligation of
the BCR and CD300a with mAb reduced BCR stimulated
Ca2+ mobilization and NFAT transcriptional activity. In
the absence of SHP-1, but not SHP-2 or SHIP, CD300a
mediated inhibition was significantly reduced. Addition-
ally, we show that superantigen induced activation was
Figure 6 SHP-1, but not SHP-2 or SHIP, is required for CD300a mediated inhibition of BCR stimulated activation. (A) DT40 cells, DT40
cells lacking SHP-1, DT40 cells lacking SHP-2, or DT40 cells lacking SHIP, all expressing CD300a WT were loaded with Fluo-4 and Fura-Red. Then,
cells were acquired in a flow cytometer and stimulated with anti-chicken BCR plus isotype control antibody (black line) or anti-chicken BCR plus
anti-CD300a (grey line) mAb for 30 seconds and then co-crosslinked with a secondary antibody (GAM). Ca2+ mobilization is expressed as the ratio
of Fluo-4/Fura-Red as a function of time. These results are representative of two independent experiments. (B) DT40 cell lines expressing CD300a
WT were transiently transfected with a NFAT luciferase reporter plasmid and stimulated with anti-chicken BCR plus isotype control or anti-chicken
BCR plus anti-CD300a mAb. Cells were lysed and supernatants assayed for luciferase activity. Results were normalized to the activity obtained
when cells were treated with PMA plus ionomycin. Data are presented as percentage of inhibition of CD300a vs. isotype control and they are the
average ± SEM for three separate experiments. (C) The indicated DT40 cells lines stably expressing CD300a WT and human SHP-1 WT, SHP-1 CS,
SHP-2 WT or SHP-2 CS were loaded with Fluo-4 and Fura-Red. Ca2+ mobilization was assessed as in A. These results are representative of three
independent experiments. (D) KIR-CD300a WT Jurkat T cells transfected with non target (NT), SHP-1 and SHP-2 siRNA were co-cultured with
721.221 or 721.221-Cw3 cells, loaded or not with SED. Cultures were harvested and Jurkat T cells were assessed for CD69 expression by flow
cytometry. In the left panel, the percentage of inhibition of CD69 expression, calculated as shown in material and methods, is presented. The
scatter plot represents the average ± SEM. In the center panel, the expression of SHP-1, SHP-2 and actin (loading control) was assessed by
western blot analysis in lysates from siRNA transfected KIR-CD300a WT Jurkat T cells. In the right panel, the relative amount of SHP-1 mRNA and
SHP-2 mRNA from siRNA transfected KIR-CD300a WT Jurkat T cells is shown. The bar graph represents the average ± SEM. Results are from three
independent experiments.
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http://www.biomedcentral.com/1471-2172/13/23inhibited when Jurkat T cells expressing the chimeric re-
ceptor KIR-CD300a were mixed with antigen presenting
cells expressing the KIR2DL2 ligand HLA-Cw3. The
interaction of KIR-CD300a with its ligand led to the
tyrosine phosphorylation of CD300a ITIM motifs. This
phosphorylation required the src kinase Lck, and pro-
vided docking sites for the binding of the phosphatases
SHP-1 and SHP-2. These early events were followed by
the inhibition of superantigen mediated up-regulation of
activation markers CD25 and CD69.
The employment of two different models in attempting
to understand CD300a inhibitory signal in lymphocytes
was very important in our studies. Since DT40 chicken B
cells do not express CD300a, the usage of these cells and
their knockout counterparts allowed us to specifically ex-
press both CD300a and phosphatases, wild type and
mutants, and to investigate the role of phosphatases in
CD300a signaling transmission. In our hands, and with
the available anti-CD300a mAb, we were unable to
immunoprecipitate CD300a (data not shown). Due to
this inability to immunoprecipitate CD300a and, because
we also were interested in an experimental system that
relies on receptor-ligand interaction, we generated the
chimeric receptor KIR-CD300a. Results obtained with
similar chimeric receptors have proved useful in gaining
information about the role of the ITIMs. For example,
by using a chimeric receptor consisting of KIR extracel-
lular domain fused to the FcγRIIb intracellular tail,
Gupta et al. demonstrated that the ITIMs in the intracel-
lular tail, and not the extracellular portion, are respon-
sible for the transmission of the inhibitory signal and
determined which phosphatase was employed [41].
For a more comprehensive understanding of CD300a
mediated signaling on lymphocytes, mutational analysis
of the ITIMs should prove helpful. Lankry et al. have
undertaken these studies using the human YTS NK cell
line [29]. Their results indicated that all of the ITIMs, in-
cluding the non-classical 4th ITIM, were important for
the inhibitory function of CD300a, with the 3rd ITIM
being the most essential. Results obtained in our labora-
tory in which we mutated tyrosine residues to phenlyala-
nine instead of to alanine, as described by Lankry et al.
[29], have confirmed that a single mutation of the 3rd
ITIM significantly decreased BCR stimulated Ca2+ re-
lease and NFAT transcriptional activity (data not shown).
In our KIR-CD300a chimera, the CD300a ITIMs were
phosphorylated upon interaction with the KIR ligand
without the requirement of superantigen stimulation.
This is not surprising, since phosphorylation of KIR
ITIMs by Lck also occurs independently of antigen
stimulation [9,42]. However, it is interesting that a single
tyrosine kinase, such as Lck, can be utilized for both in-
hibitory and activating receptors. While the mechanism
by which this occurs is still under investigation, findingsobtained by Stefanova et al. [43] may shed some light on
this conundrum. In that report, antagonist and agonist
peptides, defined by their different binding affinities to
the TCR, were used to dissect the seemingly different
roles of Lck in T cell homeostasis. The SHP-1 tyrosine
phosphatase was a central player in their findings. When
T cells were stimulated with a weak binding ligand, Lck
phosphorylated SHP-1. Subsequent association of SHP-1
with Lck mediated the recruitment of SHP-1 to the TCR
complex where it was proposed that SHP-1 then depho-
sphorylated Lck at Y394 leading to TCR desensitization.
Alternatively, upon interaction with a strong TCR ligand,
Erk was rapidly activated and phosphorylated Lck on
serine residues (S59). This serine phosphorylation
decreased the ability of Lck to bind SHP-1 and therefore
the positive signaling proceeded. Here, we have shown
that Lck is involved in CD300a phosphorylation. It may
be possible that Lck also phosphorylates CD300a bound
SHP-1, subsequently aiding in the recruitment of SHP-1
to the TCR complex, leading to the inhibition of positive
signaling. Future studies should address this hypothesis.
Our results using SHP-1 and SHP-2 knocked down
KIR-CD300a WT Jurkat T cells and specific phosphatase
deficient DT40 chicken B cells indicated that SHP-1, but
not SHP-2 or SHIP was necessary for CD300a mediated
inhibition of BCR and TCR signaling. Although mAb
cross-linking induced coimmunoprecipitation of SHIP
with CD300a in mast cells [30], the consensus binding
sequences for SHIP are different from that of SHP-1 and
SHP-2 and are not present in CD300a. SHIP has no pre-
ference for binding to residues N-terminal to the phos-
phorylated tyrosine (pY) but has a strong preference for
Leu at the +2 position. Instead, SHP SH2 domains prefer
a hydrophobic residue at the −2 position on the ITIM
[44]. All three classical ITIMs present in CD300a have
hydrophobic residues at −2 and none of them have Leu
at +2 position [28]. Therefore, while the detection of
SHIP in a complex with CD300a may indicate a role for
SHIP in the control of signaling in mast cells, its direct
binding to CD300a ITIM motifs is unlikely. On the other
hand, the consensus binding motifs for SHP-1 and SHP-
2 are similar [44] and matched sequences are found in
the CD300a intracellular tail [28]. Indeed, both SHP-1
and SHP-2 were detected in immunoprecipitates from
ligand stimulated Jurkat T cells expressing the KIR-
CD300a chimeric receptor. However, according to previ-
ously published results that tested the binding of SHP
SH2 domains to pY peptide libraries [44], it may be that
the chances of having both SH2 domains of a single
phosphatase bound simultaneously to phosphorylated
CD300a intracellular tail are greater with SHP-1. While
binding of a single SH2 domain may potentiate phos-
phatase activity, binding of both domains further
increases the activity by several fold [45].
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CD300a comes from the SHP-1 and SHP-2 reconstitu-
tion experiments. As shown in Figure 6, the expression
of either SHP-1 CS or SHP-2 CS reduced the inhibitory
function of CD300a. The mutation of the cysteine resi-
due renders the phosphatases catalytically inactive, but
they still are able to bind the target ITIM sequences and
therefore become dominant negative. In that same line
of thought, one could argue that since SHP-2 WT also
competes for CD300a ITIM occupancy, it could also
function as a dominant negative, and in fact, reconstitu-
tion of CD300a expressing DT40 chicken B cells lacking
SHP-2 with human SHP-2 WT resulted in a decrease in
the CD300a mediated inhibitory ability when compared
with non-reconstituted DT40 cells lacking SHP-2 (see
Figure 6C). Additional studies designed to address the
relative binding affinity of SHP-1 and SHP-2 to phos-
phorylated CD300a ITIMs and their differential role in
signaling should prove interesting.
Conclusions
Taken together, we have demonstrated that CD300a inhi-
bits lymphocyte immune receptor signaling via SHP-1.
Although both SHP-1 and SHP-2 are recruited to the
phosphorylated ITIMs of CD300a, only the absence of
SHP-1 limited the ability of CD300a to inhibit activation
signals. SHP-1 has historically been associated with nega-
tive signaling while SHP-2 has been associated with posi-
tive signals [18]. Beyond similarities in their SH2
domains, the two phosphatases display little sequence
homology. SHP-1 but not SHP-2 displays localization
signals in particular for lipid rafts while only SHP-2 has
proline-rich domains which could recruit SH3 domain
containing proteins [44]. However, the specific roles of
these regions may play in the function of the two phos-
phatases remains to be defined. With this in mind, the
availability of the different phosphatases to bind the
CD300a intracellular tail following receptor ligation will




The E6.1 Jurkat T cell line, the Jurkat T cell lines deficient
in Lck (JCaM1.6) [46] and ZAP-70 (P116) [47], the DT40
chicken B cell line [48], the DT40 mutant cell lines lacking
SHP-1, SHP-2 and SHIP [14,49], and the MHC class I defi-
cient human lymphoblastoid B cell line 721.221 and its
clones expressing HLA-Cw3 and -Cw6 [50,51] were all
maintained in RPMI medium containing 7.5% FBS.
To generate stable transfectants, 1 x 107 DT40 chicken
B cells or E6.1 Jurkat T cells were transfected with the
designated plasmids by electroporation. For DT40 chicken
B cells, in addition to the CD300a and phosphataseexpressing plasmids, cells were also transfected with 5 μg
of the pBABE puro vector [52]. After 48 hours in complete
medium, cells were selected with neomycin (Invitrogen) or
puromycin (Sigma). Cells were tested for CD300a expres-
sion, sorted using a FACS Aria sorter (BD Biosciences)
and positive cells were further expanded. Cells transfected
with plasmids expressing both CD300a and phosphatases
were preselected for CD300a expression, then cloned and
tested by Western blot for phosphatase expression. All
transfected DT40 chicken B cells and Jurkat T cells
expressed similar levels of CD300a and KIR-CD300a, re-
spectively (data not shown).
Antibodies used in this study were obtained from the
following vendors: PE-Cy7 anti-CD19 (clone HIB19),
Alexa Fluor 488 anti-CD25 (clone BC96), PE anti-CD69
(clone FN50) and isotype control murine IgG1κ were
purchased from eBioscience; purified anti-CD158b (clone
GL183), PE and purified anti-CD300a (clone E59.126)
were purchased from Beckman Coulter; PE anti-CD158b
(clone DX27) was purchased from BioLegend; purified
anti-chicken IgM (clone M1) was purchased from South-
ern Biotech; FITC goat anti-mouse IgG F(ab’)2 was pur-
chased from KPL; anti-HA high affinity (clone 3F10) and
3F10-HRP were purchased from Roche-Diagnostics;
rabbit anti-mouse IgG was purchased from MP Biomedi-
cals; goat anti-mouse IgG was purchased from Jackson
ImmunoResearch Laboratories; anti-phosphotyrosine
(clone 4G10), biotinylated 4G10, and anti-SHP-1 anti-
bodies were from Millipore; anti-SHP-2 (clone 79/
PTP1D/SHP2) was from BD Biosciences; anti-mouse
HRP and anti-rabbit HRP were purchased from GE
Healthcare and NeutrAvidin-HRP was from Fisher. SHP-
1 specific siRNA duplexes were from Sigma, and non-
target (NT) and SHP-2 specific siRNA duplexes were
from Dharmacon.
A plasmid encoding human CD300a was previously
described [25]. The KIR-CD300a chimeric construct was
engineered by fusing the extracellular domain of the
KIR2DL2 receptor to the transmembrane and cytoplasmic
domains of CD300a tagged with HA (Figure 2). A KIR2DL2
expressing plasmid (a generous gift of Dr. Eric O. Long)
was used as a template for the extracellular domain of
KIR2DL2. The following primers were used for the PCR
reaction: a forward primer 5’ GGGGTACCGCCGC
CATGTCGCTCATGGTCG 3’ and a reverse primer 5’
GAAGATCTGTGCAGGTGTCGGGG 3’. A pMACS
CD300a-HA plasmid (engineered in our laboratory) was
used as a template for the transmembrane and cytoplasmic
tail of CD300a tagged with HA. The following primers were
used for the PCR reaction: a forward primer 5’ GAA
GATCTCTCTGCTCCTCTCCCTGC 3’ and a reverse pri-
mer 5’ GCTCTAGATCATTAAGCGTAGTCTGG 3’. The
PCR products were purified and digested with the restric-
tion enzymes Kpn I/Bgl II and Bgl II/Xba I, respectively.
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http://www.biomedcentral.com/1471-2172/13/23Digested products were ligated into an empty pcDNA3.1
mammalian expression vector digested with Kpn I and Xba
I. Mutagenesis of CD300a and KIR-CD300a expressing
plasmids were performed with specific primers using a
Quick Change Site-directed mutagenesis kit (Stratagene).
DNA sequencing analysis confirmed the sequences of each
construct. Plasmids expressing human SHP-1 and SHP-2,
wild type (WT) and the catalytically inactive (CS mutation),
were a generous gift of Dr. Eric O. Long.Cell activation, immunoprecipitation and western blot
analyses
Jurkat T cells, 5–10 x 106, were prewarmed at 37°C, treated
with 0.1 mM sodium orthovanadate and 0.3 mM hydrogen
peroxide for 3–5 minutes and then lysed with 50 mM Tris
HCl containing 1% NP40 plus protease and phosphatase
inhibitors as previously described [53]. In other experi-
ments, Jurkat T cells were mixed with an equal number of
the indicated antigen presenting cells (721.221 cells), in
the absence or presence of staphylococcal enterotoxin D
(SED) (Toxin Technology) at 100 ng/ml while maintained
on ice and then centrifuged to promote cell to cell contact.
The supernatants were removed and the cell pellets were
incubated at 37°C and then, cells were lysed as described
above. For immunoprecipitation experiments, cell lysates
were precleared with Protein A/G beads (Pierce) for one
hour followed by precipitation with Protein A/G beads
preloaded with 1.6 μg of anti-KIR2DL2 (clone GL183).
Eluted proteins were resolved on gradient gels (Invitro-
gen), transferred to nitrocellulose and probed with the
indicated antibodies.Flow cytometry experiments
Jurkat T cells, 1 x 106, were mixed with an equal number
of 721.221 cells and distributed in wells of a 12 well plate
without or with 100 ng/ml SED. After 24 h of culture,
the expression of CD25 and CD69 by the Jurkat T cells
was assessed by flow cytometry using a FACS Calibur
(BD Biosciences). Jurkat T cells were electronically gated
by size and forward scatter and by their lack of expres-
sion of CD19, a marker expressed by the lymphoblastoid
human B cell line 721.221. In the knock down experi-
ments, prior to the mixing with 721.221 and 721.221-
Cw3 cells, KIR-CD300a WT Jurkat T cells were trans-
fected with 400 μM of the indicated siRNA duplexes
using the Amaxa Nucleofection System (Lonza). After
36 hours, the efficiency of the knock down was measured
at the mRNA and protein levels by real-time PCR and
western blot analysis, respectively. The percentage of in-
hibition of CD69 expression was calculated according to
the following formula: [(SED loaded 721.221 Mediated
CD69 induction – SED loaded 721.221-Cw3 Mediated
CD69 Induction)/SED loaded 721.221 Mediated CD69induction] x 100. CD69 expression was measured by me-
dian fluorescence intensity (MFI).
NFAT luciferase reporter assays
DT40 chicken B cells expressing CD300a or Jurkat T
cells expressing the chimeric KIR-CD300a receptor were
transiently transfected with 5 μg of an NFAT luciferase
reporter construct and cultured for 16 hours. For experi-
ments with B cells, DT40 transfectants were distributed
into duplicate wells of a 24 well plate containing medium
alone, prebound anti-mouse IgG plus anti-chicken IgM
and either isotype IgG1 control antibody or anti-CD300a
mAb. For experiments with T cells, Jurkat transfectants
were mixed with an equal number of 721.221 cells and
added to wells of a 24 well plate with or without the
superantigen, SED (100 ng/ml). As a measure for max-
imal NFAT activity, cells were treated with 50 ng/ml
phorbol myristate acetate (PMA) plus 5 μM ionomycin,
purchased from EMD. After 6 h, cells were disrupted in
lysis buffer (Promega) and lysates were assayed using
luciferin (Promega).
Calcium mobilization assays
DT40 chicken B cells, 1.5 x 106, were washed with PBS
containing 1% BSA, resuspended in 3 ml and loaded with
3 μg of Fluo-4 and 7.5 μg of Fura-Red (Invitrogen) for
30 minutes at 30°C. Then, cells were washed twice and
aliquots of 1 ml were warmed at 37°C for 5 minutes, fol-
lowed by acquisition in a flow cytometer (FACS Calibur).
To establish a baseline, cells were first acquired for
30 seconds, at which point the anti-IgM mAb plus the
anti-CD300a mAb or isotype control IgG1 were added
and acquisition was followed for another 30 seconds.
Then, the secondary antibody was added and acquisition
was followed for 5–6 minutes. Data were analyzed using
the FlowJo software (Treestar).
Statistical analysis
Data were analyzed using GraphPad Prism software. The
data were plotted as bar graphs or scatter plots, and pair
wise comparisons were examined by two-tailed paired Stu-
dent’s t-test. NS: non significant; * P< 0.05, ** P< 0.01;
*** P< 0.001.
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